Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTGER2 | P43116 | 13/20 | 0.82 |
| ▸ | CA12 | O43570 | 4/20 | 0.63 |
| ▸ | CA1 | P00915 | 4/20 | 0.63 |
| ▸ | CA2 | P00918 | 4/20 | 0.63 |
| ▸ | CA4 | P22748 | 4/20 | 0.63 |
| ▸ | CA9 | Q16790 | 4/20 | 0.63 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6281587 | 0.93 | PTGER2 (0.71) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL1147570 | 0.91 | PTGER2 (0.81) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL533264 | 0.90 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL29376960 | 0.90 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL13407391 | 0.90 | PTGER2 (0.86) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147493 | 0.90 | PTGER2 (1.00) | PTGER2CA12CA1CA2CA4 | |
| SCHEMBL6281961 | 0.90 | PTGER2 (0.67) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147489 | 0.90 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147494 | 0.90 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 | |
| Evatanepag SCHEMBL1147496 | 0.90 | PTGER2 (0.98) | PTGER2CA12CA1CA2CA4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7442702-B2 | Treatment of bone disorders; carboxy derivatives | PFIZER INC. (US) | 2008-10-28 | — | — | US | disclosed |
| EP-1021410-B1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER (US) | 2006-12-27 | — | — | EP | disclosed |
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | PFIZER INC | 2005-03-24 | — | — | US | disclosed |
| US-6498172-B1 | (3-(((4-TERT-BUTYL-BENZYL)-(PYRIDINE-3-SULFONYL)-AMINO)-METHYL) -PHENOXY)-ACETIC ACID OR SALT; TREATING SUCH AS OSTEOPOROSIS | PFIZER INC. | 2002-12-24 | — | — | US | disclosed |
| EP-1021410-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 2000-07-26 | — | — | EP | disclosed |
| WO-1999019300-A1 | PROSTAGLANDIN AGONISTS AND THEIR USE TO TREAT BONE DISORDERS | PFIZER INC. (US) | 1999-04-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050065133-A1 | Pharmaceutical compositions and methods comprising combinations of 2-alkylidene-19-nor-vitamin D derivatives and an EP2 or EP4 selective agonist | VDR, CYP24A1, CYP2R1 | PTGER2 4/4885CA12 2289/4885CA1 3183/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.